Pharsight

Drugs that contain Ketorolac Tromethamine

1. Acular Ls patents expiration

ACULAR LS Litigations
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(3 years from now)

Market Authorisation Date: 30 May, 2003

Treatment: A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating ocular pain; A method of treating or preventing ocular pain and burning; A method of treating ...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's drug patent expiration?
More Information on Dosage

ACULAR LS family patents

Family Patents

2. Acuvail patents expiration

ACUVAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7842714 ALLERGAN Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(5 months from now)

US9192571 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Mar, 2028

(4 years from now)

US8512717 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Mar, 2028

(4 years from now)

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage

ACUVAIL family patents

Family Patents